Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma

Molecular Therapy

Volumn 21, Issue 5, 2013, Pages 1034-1043

  Di Carlo, Emma ^a   Bocca, Paola ^b   Emionite, Laura ^c   Cilli, Michele ^c   Cipollone, Giuseppe ^a   Morandi, Fabio ^b   Raffaghello, Lizzia ^b   Pistoia, Vito ^b   Prigione, Ignazia ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHANGIOGENESIS; MOUSE; NEUROBLASTOMA; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR CELL; TUMOR VASCULARIZATION; VGAMMA9VDELTA2 T LYMPHOCYTE;

MUS;

EID: 84877031179     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.38     Document Type: Conference Paper

References (50)

1. Maris, JM, Hogarty, MD, Bagatell, R and Cohn, SL (2007). Neuroblastoma. Lancet 369: 2106-2120.
2. DuBois, SG, Kalika, Y, Lukens, JN, Brodeur, GM, Seeger, RC, Atkinson, JB et al. (1999). Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21: 181-189.
3. Matthay, KK, Reynolds, CP, Seeger, RC, Shimada, H, Adkins, ES, Haas-Kogan, D et al. (2009). Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 27: 1007-1013.
4. Seeger, RC (2011). Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol 21: 229-237.
5. Prigione, I, Corrias, MV, Airoldi, I, Raffaghello, L, Morandi, F, Bocca, P et al. (2004). Immunogenicity of human neuroblastoma. Ann N Y Acad Sci 1028: 69-80.
6. Morandi, F, Levreri, I, Bocca, P, Galleni, B, Raffaghello, L, Ferrone, S et al. (2007). Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res 67: 6433-6441.
7. Castriconi, R, Dondero, A, Augugliaro, R, Cantoni, C, Carnemolla, B, Sementa, AR et al. (2004). Identification of 4Ig-B7-H3 as a neuroblastoma- associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA 101: 12640-12645.
8. Raffaghello, L, Prigione, I, Airoldi, I, Camoriano, M, Morandi, F, Bocca, P et al. (2005). Mechanisms of immune evasion of human neuroblastoma. Cancer Lett 228: 155-161.
9. Soldati, R, Berger, E, Zenclussen, AC, Jorch, G, Lode, HN, Salatino, M et al. (2012). Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int J Cancer 131: 1131-1141.
10. Raffaghello, L, Prigione, I, Bocca, P, Morandi, F, Camoriano, M, Gambini, C et al. (2005). Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 24: 4634-4644.
11. Foreman, NK, Rill, DR, Coustan-Smith, E, Douglass, EC and Brenner, MK (1993). Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer 67: 933-938.
12. Schilbach, KE, Geiselhart, A, Wessels, JT, Niethammer, D and Handgretinger, R (2000). Human gammadelta T lymphocytes exert natural and IL-2-induced cytotoxicity to neuroblastoma cells. J Immunother 23: 536-548.
13. Schilbach, K, Frommer, K, Meier, S, Handgretinger, R and Eyrich, M (2008). Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy. J Immunother 31: 896-905.
14. Pistoia, V, Bianchi, G, Borgonovo, G and Raffaghello, L (2011). Cytokines in neuroblastoma: from pathogenesis to treatment. Immunotherapy 3: 895-907.
15. De Rosa, SC, Andrus, JP, Perfetto, SP, Mantovani, JJ, Herzenberg, LA, Herzenberg, LA et al. (2004). Ontogeny of gamma delta T cells in humans. J Immunol 172: 1637-1645.
16. Morita, CT, Jin, C, Sarikonda, G and Wang, H (2007). Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev 215: 59-76.
17. Gober, HJ, Kistowska, M, Angman, L, Jenö, P, Mori, L and De Libero, G (2003). Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197: 163-168.
18. Mattarollo, SR, Kenna, T, Nieda, M and Nicol, AJ (2007). Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer Immunol Immunother 56: 1285-1297.
19. Benzaïd, I, Mönkkönen, H, Stresing, V, Bonnelye, E, Green, J, Mönkkönen, J et al. (2011). High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res 71: 4562-4572.
20. Luckman, SP, Hughes, DE, Coxon, FP, Graham, R, Russell, G and Rogers, MJ (1998). Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581-589.
21. Peng, H, Sohara, Y, Moats, RA, Nelson, MD Jr, Groshen, SG, Ye, W et al. (2007). The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res 67: 9346-9355.
22. Bäckman, U, Svensson, A, Christofferson, RH and Azarbayjani, F (2008). The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res 28(3A): 1551-1557.
23. Coscia, M, Quaglino, E, Iezzi, M, Curcio, C, Pantaleoni, F, Riganti, C et al. (2010). Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 14: 2803-2815.
24. Green, JR and Guenther, A (2011). The backbone of progress-preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol 77 Suppl 1: S3-S12.
25. Gnant, M and Clézardin, P (2012). Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev 38: 407-415.
26. Clézardin, P and Massaia, M (2010). Nitrogen-containing bisphosphonates and cancer immunotherapy. Curr Pharm Des 16: 3007-2014.
27. Kondo, M, Sakuta, K, Noguchi, A, Ariyoshi, N, Sato, K, Sato, S et al. (2008). Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 10: 842-856.
28. Sato, K, Kimura, S, Segawa, H, Yokota, A, Matsumoto, S, Kuroda, J et al. (2005). Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 116: 94-99.
29. Bonneville, M and Scotet, E (2006). Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 18: 539-546.
30. Bonneville, M and Scotet, E (2006). Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 18: 539-546.
31. Nussbaumer, O, Gruenbacher, G, Gander, H and Thurnher, M (2011). DC-like celldependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by d T lymphocytes. Blood 118: 2743-2751.
32. Bouet-Toussaint, F, Cabillic, F, Toutirais, O, Le Gallo, M, Thomas de la Pintière, C, Daniel, P et al. (2008). Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother 57: 531-539.
33. Castella, B, Vitale, C, Coscia, M and Massaia, M (2011). V9Vd2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cell Mol Life Sci 68: 2419-2432.
34. Nicol, AJ, Tokuyama, H, Mattarollo, SR, Hagi, T, Suzuki, K, Yokokawa, K et al. (2011). Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 105: 778-786.
35. Morgan, G and Lipton, A (2010). Antitumor effects and anticancer applications of bisphosphonates. Semin Oncol 37 Suppl 2: S30-S40.
36. Clézardin, P (2011). Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 48: 71-79.
37. Nishio, N, Fujita, M, Tanaka, Y, Maki, H, Zhang, R, Hirosawa, T et al. (2012). Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human d T cells. J Immunother 35: 598-606.
38. Engler, S, Thiel, C, Förster, K, David, K, Bredehorst, R and Juhl, H (2001). A novel metastatic animal model reflecting the clinical appearance of human neuroblastoma: growth arrest of orthotopic tumors by natural, cytotoxic human immunoglobulin M antibodies. Cancer Res 61: 2968-2973.
39. Khanna, C, Jaboin, JJ, Drakos, E, Tsokos, M and Thiele, CJ (2002). Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo 16: 77-85.
40. Otto, M, Barfield, RC, Martin, WJ, Iyengar, R, Leung, W, Leimig, T et al. (2005). Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin Cancer Res 11: 8486-8491.
41. Pezzolo, A, Parodi, F, Corrias, MV, Cinti, R, Gambini, C and Pistoia, V (2007). Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol 25: 376-383.
42. Hendrix, MJ, Seftor, EA, Hess, AR and Seftor, RE (2003). Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3: 411-421.
43. Carmeliet, P and Jain, RK (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
44. Tammela, T and Alitalo, K (2010). Lymphangiogenesis: Molecular mechanisms and future promise. Cell 140: 460-476.
45. Yamashita, J, Koi, K, Yang, DY and McCauley, LK (2011). Effect of zoledronate on oral wound healing in rats. Clin Cancer Res 17: 1405-1414.
46. Groom, JR and Luster, AD (2011). CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89: 207-215.
47. Russell, HV, Groshen, SG, Ara, T, DeClerck, YA, Hawkins, R, Jackson, HA et al. (2011). A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer 57: 275-282.
48. Chen, T, Berenson, J, Vescio, R, Swift, R, Gilchick, A, Goodin, S et al. (2002). Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42: 1228-1236.
49. Di Paolo, D, Loi, M, Pastorino, F, Brignole, C, Marimpietri, D, Becherini, P et al. (2009). Liposome-mediated therapy of neuroblastoma. Meth Enzymol 465: 225-249.
50. Morandi, F, Chiesa, S, Bocca, P, Millo, E, Salis, A, Solari, M et al. (2006). Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia 8: 833-842.